Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis
| العنوان: | Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis |
|---|---|
| المؤلفون: | Martin Zeitz, Isrid Sturm, Patricia Grabowski, Heinz-Johannes Buhr, Kerstin Maaser, Peter T. Daniel, Katharina Schelwies, Bernd Dörken, Hans Scherübl |
| المصدر: | International Journal of Colorectal Disease. 21:221-230 |
| بيانات النشر: | Springer Science and Business Media LLC, 2005. |
| سنة النشر: | 2005 |
| مصطلحات موضوعية: | Adult, Male, Oncology, medicine.medical_specialty, Colorectal cancer, Disease, Neuroendocrine differentiation, Gastroenterology, Bcl-2-associated X protein, Internal medicine, Humans, Medicine, Stage (cooking), Survival analysis, Aged, Neoplasm Staging, Retrospective Studies, bcl-2-Associated X Protein, Aged, 80 and over, biology, business.industry, Cancer, Middle Aged, Hepatology, Genes, p53, Prognosis, medicine.disease, Survival Analysis, Treatment Outcome, biology.protein, Female, Colorectal Neoplasms, business |
| الوصف: | Neuroendocrine differentiation is an independent prognostic factor in colorectal cancer. Moreover, an altered p53/BAX pathway is associated with a poor clinical outcome in Union Internationale Contre le Cancer (UICC) stage III disease. Because these markers are involved in different genetic events disrupted in colorectal cancer, we investigated the prognostic power of a multimarker analysis. Specimens were analyzed from 59 patients with UICC stage III disease who underwent surgery for colorectal adenocarcinoma at our institution and were followed up for 5 years or until death. Tumors were studied for both p53 mutation and BAX protein expression as well as for the expression of neuroendocrine markers. Statistical analysis of each marker alone or in combination was performed. p53 status/BAX expression and neuroendocrine differentiation are not correlated in stage III colorectal cancers. However, the combination of both independent events identified a subgroup of patients with an excellent prognosis: Patients whose tumors were neuroendocrine marker-negative and who exhibited an intact p53/BAX pathway lived longer (mean survival, 93 months; range, 82–104 months) than patients whose tumors were either neuroendocrine marker-positive or whose tumors had a completely disrupted apoptotic pathway (41 months; range, 26–57 months; p |
| تدمد: | 1432-1262 0179-1958 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eec5f3c5e83637b66328815f3cb2baa https://doi.org/10.1007/s00384-005-0779-5 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....3eec5f3c5e83637b66328815f3cb2baa |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14321262 01791958 |
|---|